Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

indero gene expression analysis

Indero validates three-day gene expression method

, 13 December 2025/in E-News /by panglobal

Montreal-based contract research organisation Indero has completed an internally funded study demonstrating that quantitative gene expression analysis can assess topical new chemical entities in early-phase clinical research within three days, substantially reducing the time and cost associated with traditional evaluation methods.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/12/indero-gene-expression-analysis.jpg 1047 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-13 10:37:112025-12-11 10:51:45Indero validates three-day gene expression method
Johnson and Johnson Logo.svg

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion

, 12 December 2025/in E-News /by panglobal

Johnson & Johnson has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. for US$3.05 billion in cash, securing access to a clinical-stage prostate cancer therapy and a proprietary platform technology designed to develop oral targeted treatments for solid tumours. The transaction is expected to close within the coming months pending antitrust clearance […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/12/Johnson_and_Johnson_Logo.svg_.png 233 1280 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-12 10:32:542025-12-11 10:36:53Johnson & Johnson acquires Halda Therapeutics for $3.05 billion
alphasync

New AlphaSync database ensures protein structure predictions stay current

, 11 December 2025/in E-News /by panglobal

St. Jude Children’s Research Hospital scientists have launched AlphaSync, a free database addressing a critical gap in structural biology by continuously synchronising predicted protein structures with the latest sequence data from UniProt. The resource currently provides 2.6 million updated structural models across 925 species, including disease-relevant proteins previously missing from existing databases.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/12/alphasync.jpg 1258 1883 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-11 16:18:432025-12-11 16:18:43New AlphaSync database ensures protein structure predictions stay current
metabolomics research competition

NADMED launches $30,000 metabolomics competition

, 11 December 2025/in E-News /by panglobal

A Finnish biotechnology company has opened applications for a global scientific competition designed to advance understanding of cellular redox metabolism, offering successful applicants access to precision measurement technology and expert support valued at up to $30,000.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/12/NADMED.jpg 1280 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-12-11 10:28:102025-12-11 10:32:33NADMED launches $30,000 metabolomics competition
Molcure AI drug discovery

Molcure partners with Boehringer Ingelheim to accelerate AI-driven antibody drug discovery

, 9 November 2025/in E-News /by panglobal

MOLCURE Inc. has announced a multiyear strategic research agreement with Boehringer Ingelheim to discover innovative antibody therapeutics for multiple targets using the Japanese company’s proprietary artificial intelligence platform technology. The collaboration will combine MOLCURE’s AI-driven platform with Boehringer Ingelheim’s expertise in biologics development, aiming to expand the scope and efficiency of antibody drug discovery beyond […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/11/Molcure-AI-drug-discovery.png 1707 1707 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-11-09 16:02:462025-11-06 16:08:36Molcure partners with Boehringer Ingelheim to accelerate AI-driven antibody drug discovery
StemInov stem cells

StemInov secures €10.6 million to advance mesenchymal stem cell therapy for severe pneumonia

, 8 November 2025/in E-News /by panglobal

French biopharmaceutical company StemInov has closed a €10.6 million financing round to support the industrialisation of its stem cell platform and prepare for Phase I/IIa clinical trials targeting severe pneumonia complications. The Nancy and Illkirch-Graffenstaden-based company, which specialises in mesenchymal stem cell (MSC) therapies for inflammatory and autoimmune diseases, expects to initiate patient recruitment in […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/11/StemInov_stem_cells.jpg 1184 864 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-11-08 16:25:292025-11-06 16:29:11StemInov secures €10.6 million to advance mesenchymal stem cell therapy for severe pneumonia
ARPA H Owlstone

Owlstone Medical secures US$49.1 million ARPA-H funding for at-home cancer detection technology

, 6 November 2025/in E-News /by panglobal

Cambridge-based Owlstone Medical has been awarded up to US$49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop a multi-cancer early detection test that can be performed at home using breath and urine samples. The funding forms part of ARPA-H’s Platform Optimising SynBio for Early Intervention and Detection in Oncology (POSEIDON) programme, […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/11/ARPA-H_Owlstone.jpg 1446 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-11-06 18:30:232025-11-06 18:30:23Owlstone Medical secures US$49.1 million ARPA-H funding for at-home cancer detection technology
Scherm­afbeelding 2025 11 06 om 19.22.30

Theranexus rebrands as THX Pharma signals, shift to commercial pharmaceutical development

, 6 November 2025/in E-News /by panglobal

French pharmaceutical company Theranexus has announced its transformation into THX Pharma, marking a strategic pivot from biotechnology research towards regulatory approval and commercial deployment of treatments for rare neurological diseases. The rebranding of the Lyon-based company positions it to advance two lead drug candidates through registration and international market access.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/11/Scherm­afbeelding-2025-11-06-om-19.22.30.png 445 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-11-06 18:25:222025-11-06 18:25:22Theranexus rebrands as THX Pharma signals, shift to commercial pharmaceutical development
neogap tumour specific T cells

Neogap receives Chinese patent for tumour-specific T cell expansion technology

, 6 November 2025/in E-News /by panglobal

Neogap Therapeutics AB has been granted Chinese patent protecting its proprietary method for expanding tumour-specific T cells, marking a significant milestone in the company’s international intellectual property strategy. The patent, which provides legal protection until 2038, covers a core manufacturing process for the company’s personalised cell-based immunotherapy, pTTL, currently under evaluation in Phase I/II clinical […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/11/neogap_tumour-specific-T-cells.jpg 1024 1024 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-11-06 18:12:572025-11-06 18:12:57Neogap receives Chinese patent for tumour-specific T cell expansion technology
everzom

EVerZom secures €10 million to advance exosome-based therapies for inflammatory diseases

, 6 November 2025/in E-News /by panglobal

French biotechnology company EVerZom has closed a €10 million funding round to support clinical development of its exosome-based therapeutic platform, with lead candidate EVerGel set to enter human trials in 2026 for treatment of complex perianal fistulas in Crohn’s disease.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2025/11/everzom.jpg 932 1735 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2025-11-06 18:08:462025-11-06 18:08:46EVerZom secures €10 million to advance exosome-based therapies for inflammatory diseases
Page 1 of 228123›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 December 2025

Indero validates three-day gene expression method

12 December 2025

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion

11 December 2025

New AlphaSync database ensures protein structure predictions stay current

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription